Jacob Johnson
Stock Analyst at Stephens & Co.
(2.83)
# 1,656
Out of 5,115 analysts
78
Total ratings
45.76%
Success rate
8.67%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $262.60 | -8.61% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.31 | -4.91% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $8.69 | -30.96% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $38.88 | +54.32% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $218.89 | +43.91% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $578.61 | +17.52% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $149.37 | +13.81% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $2.40 | +108.77% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.91 | +1,113.06% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $15.58 | +143.90% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.51 | +78.76% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.33 | +7.30% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $64.09 | +35.75% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $231.12 | +68.74% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $12.06 | +49.25% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.24 | +383.87% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $21.80 | +33.03% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $192.10 | -32.33% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $210.48 | +79.11% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $262.60
Upside: -8.61%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.31
Upside: -4.91%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $8.69
Upside: -30.96%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $38.88
Upside: +54.32%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $218.89
Upside: +43.91%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $578.61
Upside: +17.52%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $149.37
Upside: +13.81%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.40
Upside: +108.77%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.91
Upside: +1,113.06%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $15.58
Upside: +143.90%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.51
Upside: +78.76%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.33
Upside: +7.30%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $64.09
Upside: +35.75%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $231.12
Upside: +68.74%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $12.06
Upside: +49.25%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.24
Upside: +383.87%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $21.80
Upside: +33.03%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $192.10
Upside: -32.33%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $210.48
Upside: +79.11%